As part of its plan to consolidate its operations, Zelira Therapeutics, an Australian medical cannabis company, has relocated its headquarters and leadership to Plymouth Meeting, writes John George for the Philadelphia Business Journal.
Dr. Oludare Odumosu, the company’s new global managing director and CEO, will be based at their new 4,000-square-foot offices in Montgomery County. He is replacing Dr. Richard Hopkins, who will remain with the company until the end of May to support them through this transition period.
The move to the new location will make it possible for Zelira to “optimize its exposure” to the fast expanding U.S. cannabis market, while also growing its revenues in other markets, according to Osagie Imasogie, the company’s chairman.
“The United States continues to be a very, very exciting market for [cannabis- and cannabinoid-based and hemp-derived] product development, product launch and revenue generation,” Odumosu said.
He added that Zelira has set apart them from competitors by focusing “on developing products that have some kind of clinical validation, whether it’s in the form of real-life clinical evidence or clinical trial results.”
The new headquarters will be home to ten employees.
Read more about Zelira Therapeutics at the Philadelphia Business Journal by clicking here.